Literature DB >> 19887762

Spectral karyotypic and comparative genomic analysis of the endocrine pancreatic tumor cell line BON-1.

Juan R Lopez1, Sandra M H Claessen, Merryn V E Macville, Jozefa C M Albrechts, Britt Skogseid, Ernst-Jan M Speel.   

Abstract

BON-1 is a human serotonin-producing endocrine pancreatic tumor (EPT) cell line, which has been used for various studies of tumorigenesis and treatment. Because its genotype, phenotype and degree of differentiation may underlie events that are instrumental to the development of endocrine tumors and, moreover, may vary between labs and over time, we decided to comprehensively characterize the chromosomal constitution of BON-1 by applying conventional GTG-banding, spectral karyotyping (SKY), comparative genomic hybridization (CGH) and fluorescence in situ hybridization (FISH). BON-1 cells proved to be hyperdiploid containing a modal chromosome number of 57 (range 56-64). SKY identified a stemline containing 6 clonal aberrations including del(1p), t(9;12)del(9p)x2, der(10)t(5;10), der(19)t(8;19), der(14)t(9;14)t(9;10), and a sideline harboring an additional del(12q). CGH and FISH confirmed the SKY results and, in addition, highlighted the chromosomal regions involved in the rearrangements. Moreover, they identified a homozygous deletion of the key tumor suppressor genes CDKN2A and CDKN2B at 9p21.3, in accordance with absence of p16(INK4A) and p14(ARF) expression as revealed by immunocytochemistry. Apart from deregulation of the cell cycle and p53 pathway this finding indicates escape from replicative senescence (induced by mutated NRAS) and detachment-induced apoptosis as molecular mechanisms underlying the tumorigenesis of BON-1 cells. Immunostaining results for p53, MDM2 and pRb expression were consistent with previously published data using Western analysis. In conclusion, we provide here a comprehensive cytogenetic profile of BON-1. This cell line harbors both numerical and structural genomic alterations indicative for malignant EPTs. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19887762     DOI: 10.1159/000254483

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  6 in total

1.  Stathmin in pancreatic neuroendocrine neoplasms: a marker of proliferation and PI3K signaling.

Authors:  Simon Schimmack; Andrew Taylor; Ben Lawrence; Hubertus Schmitz-Winnenthal; Lars Fischer; Markus W Büchler; Irvin M Modlin; Mark Kidd; Laura H Tang
Journal:  Tumour Biol       Date:  2014-09-30

Review 2.  Islet biology, the CDKN2A/B locus and type 2 diabetes risk.

Authors:  Yahui Kong; Rohit B Sharma; Benjamin U Nwosu; Laura C Alonso
Journal:  Diabetologia       Date:  2016-05-07       Impact factor: 10.122

3.  Establishment and Characterization of a Human Neuroendocrine Tumor Xenograft.

Authors:  Zhaoying Yang; Le Zhang; Stefano Serra; Calvin Law; Alice Wei; Tracy L Stockley; Shereen Ezzat; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2016-06       Impact factor: 3.943

4.  Viral load, gene expression and mapping of viral integration sites in HPV16-associated HNSCC cell lines.

Authors:  Nadine C Olthof; Christian U Huebbers; Jutta Kolligs; Mieke Henfling; Frans C S Ramaekers; Iris Cornet; Josefa A van Lent-Albrechts; Alexander P A Stegmann; Steffi Silling; Ulrike Wieland; Thomas E Carey; Heather M Walline; Susanne M Gollin; Thomas K Hoffmann; Johan de Winter; Bernd Kremer; Jens P Klussmann; Ernst-Jan M Speel
Journal:  Int J Cancer       Date:  2014-08-14       Impact factor: 7.396

5.  Generation and characterization of CRISPR/Cas9-mediated MEN1 knockout BON1 cells: a human pancreatic neuroendocrine cell line.

Authors:  Azita Monazzam; Su-Chen Li; Hanna Wargelius; Masoud Razmara; Duska Bajic; Jia Mi; Jonas Bergquist; Joakim Crona; Britt Skogseid
Journal:  Sci Rep       Date:  2020-09-03       Impact factor: 4.379

6.  A Comprehensive Molecular Characterization of the Pancreatic Neuroendocrine Tumor Cell Lines BON-1 and QGP-1.

Authors:  Kim B Luley; Shauni B Biedermann; Axel Künstner; Hauke Busch; Sören Franzenburg; Jörg Schrader; Patricia Grabowski; Ulrich F Wellner; Tobias Keck; Georg Brabant; Sebastian M Schmid; Hendrik Lehnert; Hendrik Ungefroren
Journal:  Cancers (Basel)       Date:  2020-03-14       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.